3D打印技术辅助腹腔镜解剖性肝Ⅷ段切除术的应用价值

Application value of three-dimensional printing technology assisted laparoscopic anatomic liver resection of segment 8

  • 摘要:
    目的 探讨3D打印技术辅助腹腔镜解剖性肝Ⅷ段切除术(Lap‑S8)的应用价值。
    方法 采用回顾性描述性研究方法。收集2019年1月至2020年12月湖南省人民医院收治的8例肝癌(7例肝细胞癌、1例肝内胆管细胞癌)行3D打印技术辅助Lap‑S8病人的临床病理资料;男7例,女1例;中位年龄为56.5岁,年龄范围为49.0~80.0岁。8例肝癌病人中,6例行腹腔镜解剖性肝Ⅷ段全切除术,1例行腹腔镜解剖性肝Ⅷ段腹侧亚段切除术,1例行腹腔镜解剖性肝Ⅷ段背侧亚段切除术。8例病人均采用3D打印技术辅助术前评估和术中导航。观察指标:(1)手术情况。(2)术后情况。(3)随访情况。采用门诊、互联网和电话方式进行随访,了解病人术后生存及肿瘤复发情况。随访时间截至2021年3月。正态分布的计量资料以x±s表示,偏态分布的计量资料以M(范围)表示。计数资料以绝对数表示。
    结果 (1)手术情况:8例病人均顺利完成3D打印技术辅助Lap‑S8,无中转开腹。8例病人手术时间为(216±41)min,肝门阻断时间为(56±11)min,术中出血量为75 mL(50~300 mL)。8例病人无术中输血,手术切缘均为阴性。(2)术后情况:8例病人术后住院时间为(9±3)d。8例病人均未发生术后出血、胆瘘、肝脓肿和腹腔感染等并发症。(3)随访情况:8例病人均获得随访,随访时间为3.0~24.0个月,中位随访时间为12.5个月。随访期间,8例病人中,1例术前诊断为复发性肝细胞癌病人于术后5个月发生肿瘤复发,病人再次行腹腔镜手术,并采用经导管动脉化疗栓塞术和靶向治疗后带瘤生存;其余7例病人无肿瘤复发。
    结论 3D打印技术辅助Lap‑S8安全、可行。

     

    Abstract:
    Objective To investigate the application value of three‑dimensional (3D) printing technology assisted laparoscopic anatomic liver resection of segment 8 (Lap‑S8).
    Methods The retrospective and descriptive study was conducted. The clinicopathological data of 8 liver cancer patients including 7 cases with hepatocellular carcinoma and 1 case with intrahepatic cholangio-carcinoma who underwent 3D printing technology assisted Lap‑S8 in the Hunan Provincial People′s Hospital from January 2019 to December 2020 were collected. There were 7 males and 1 female, aged from 49.0 to 80.0 years, with a median age of 56.5 years. Of the 8 patients, 6 cases underwent laparoscopic anatomic liver resection of the entire segment 8, 1 case underwent laparoscopic anatomic liver resection of ventral subsegmental of the segment 8 and 1 case underwent laparoscopic anatomic liver resection of dorsal subsegmental of the segment 8. 3D printing technology was used to assist preoperative evaluation and intraoperative navigation for all 8 patients. Observation indicators: (1) surgical situations; (2) postoperative situations; (3) follow‑up. Follow‑up was conducted using outpatient examination, internet or telephone interview to detect survival and tumor recurrence of patients after operation up to March 2021. Measurement data with normal distribution were represented as Mean±SD, and measurement data with skewed distribution were represented as M(range). Count data were described as absolute numbers.
    Results (1) Surgical situations: all the 8 patients underwent 3D printing technology assisted Lap‑S8 successfully, without conversion to open surgery. The operation time, hepatic portal occlusion time and volume of intraoperative blood loss of the 8 patients were (216±41)minutes, (56±11)minutes and 75 mL(range, 50 to 300 mL), respectively. There was no intraoperative blood transfusion in 8 patients, and the surgical margin of the 8 patients was negative. (2) Postoperative situations: the duration of postoperative hospital stay of the 8 patients were (9±3)days. There was no complication such as postoperative hemorrhage, biliary fistula, liver abscess or abdominal infection occurred. (3) Follow‑up: all the 8 patients were followed up for 3.0‒24.0 months, with a median follow‑up time of 12.5 months. During the follow‑up, 1 of 8 patients with preoperative diagnosis of recurrent hepatocellular carcinoma developed tumor recurrence at 5 months after operation. The patient underwent laparoscopic surgery followed with the transcatheter arterial chemoembolization and target therapy, and survived with tumor. There was no tumor recurrence in the other 7 patients.
    Conclusion 3D printing technology assisted Lap‑S8 is safe and feasible.

     

/

返回文章
返回